ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
The choice of control means that a US or European approval for Ambrx's ARX788 may not be possible based on ACE-Breast-02 study data.
The choice of control means that a US or European approval for Ambrx's ARX788 may not be possible based on ACE-Breast-02 study data.
What's Your Reaction?
